Comparing FAPI and FDG PET Imaging in Cancer Patients
Application of FAPI and FDG PET Imaging in Patients With Different Types of Cancer
This study is testing if a new type of cancer imaging called FAPI is better than the usual FDG PET scan for helping doctors find and diagnose different kinds of cancer in adults.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University Academic / other |
| Locations | 1 site (Chongqing, Chongqing Municipality) |
| Trial ID | NCT06284070 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the effectiveness of fibroblast activation protein inhibitors (FAPI) compared to traditional 18F-FDG PET imaging in diagnosing various types of cancer. It will involve adult patients with suspected or newly diagnosed malignant tumors who will undergo both imaging techniques within a week. Clinical data, including tumor markers and imaging results, will be collected and analyzed to assess the performance of these imaging modalities in identifying primary and metastatic lesions. The study is set to run from January 2024 to December 2029.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with suspected or newly diagnosed malignant tumors.
Not a fit: Patients who are pregnant or have conditions that prevent them from undergoing imaging will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a more accurate imaging alternative for cancer diagnosis, potentially improving patient outcomes.
How similar studies have performed: While the use of FAPI in imaging is emerging, this specific comparative approach has not been widely tested, making it a novel investigation.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Adult patients (≥ 18 years old); 2. Suspected or newly diagnosed malignant tumor patients; 3. Patients who underwent 18F-FDG and 18F-FAPI PET scans within one week; 4. Patients who are able to provide informed consent forms (signed by participants, parents, or legal representatives) and consent forms in accordance with the guidelines of the Clinical Research Ethics Committee. Exclusion Criteria: 1. Pregnant women; 2. Scanned images with poor image quality due to factors such as body movement; 3. Patients with mental illness or other unsuitable conditions for examination, poor compliance, etc.
Where this trial is running
Chongqing, Chongqing Municipality
- Department of Nuclear Medicine, Daping Hospital of Army Medical University — Chongqing, Chongqing Municipality, China (Recruiting)
Study contacts
- Study coordinator: Xiao Chen, Ph.D
- Email: xiaochen229@foxmail.com
- Phone: 15922970174
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.